Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema
NCT ID: NCT03385382
Last Updated: 2018-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2016-12-06
2017-06-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema
NCT05271539
Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema
NCT04089605
Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only.
NCT04601675
Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema:
NCT05847088
OCT and OCT-Angiography Biomarkers of Treatment Response to Dexamethasone Implant in Macular Edema Due to Retinal Vascular Diseases - DME and RVO
NCT06332690
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dexamethasone group
Patients with diabetic macular edema receiving dexamethasone
Dexamethasone intravitreal implant 0.7 mg
Intravitreal Implant of dexamethasone
ranibizumab
Patients with diabetic macular edema receiving ranibizumab
Ranibizumab Injection
Injection of ranibizumab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexamethasone intravitreal implant 0.7 mg
Intravitreal Implant of dexamethasone
Ranibizumab Injection
Injection of ranibizumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BCVA greater than 0.5 LogMAR in the study eye at baseline examination
* Presence of recent DME
* CMT \> 300µm as measured using the SD-OCT at the baseline examination
Exclusion Criteria
* Laser treatments
* Prior ocular trauma
* Retinal vascular diseases
* Vitreo-retinal interface diseases
* Medium lens opacities (according to Lens Opacities Classification System)
19 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
G. d'Annunzio University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
LISA TOTO
Researcher
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UChieti
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.